Shajini
DealFlow Weekly — Wk 26 · 2026 · Synopulse DealFlow WeeklyOn a deep pine background, a faint network of the week’s thirty-five deals fades in while a gold deal line draws across and five gold molecular-ring nodes bloom along it, beside the DealFlow Weekly wordmark and the tagline a weekly readout from Synopulse. SYNOPULSE — … Read more
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.
While the industry debated whether GLP-1 mania had peaked, Eli Lilly closed seven acquisitions in 134 days.
The EU’s Critical Medicines Act takes direct aim at the supply chain vulnerabilities that leave patients without essential drugs when it matters most.
February 2026 recorded 218 biopharma transactions totalling $53B in disclosed value.
Lilly acquires Ventyx to expand oral inflammation pipeline.
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Valued Over $1B Pulse: Compass Pathways Partners With Radial to Shape Psilocybin Care Delivery Pulse: Bial Launches KYNMOBI in the UK for Parkinson’s OFF Episodes Pulse: NeuraLight Completes Landmark Parkinson’s Biomarker Trial Pulse: EA Pharma Initiates Phase 3 Evenamide Trial in Schizophrenia Pulse: Rapport Therapeutics … Read more
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
Eli Lilly has signed a new collaboration with Nimbus Therapeutics worth up to $1.3B to develop a novel oral obesity drug.